Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
about
Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistanceMineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectivesMineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart FailureCardio-renal syndromeSpironolactone in the treatment of congestive heart failure.New perspectives on the role of aldosterone excess in cardiovascular disease.Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.GPR48 increases mineralocorticoid receptor gene expression.Decongestion in acute heart failure.Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.Aquaporin-2 abundance in the renal collecting duct: new insights from cultured cell models.Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy.Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists.Current Approach to Decongestive Therapy in Acute Heart Failure.Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.Diuretic Strategies in Acute Decompensated Heart Failure.Treatment Approaches to Congestion Relief in Acute Decompensated HF: Insights After DOSE-AHF and CARRESS-HF.A perspective on diuretic resistance in chronic congestive heart failure.Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.A combined clinical and biomarker approach to predict diuretic response in acute heart failure.Increased Spironolactone in Advanced Heart Failure: Effect of Doses Greater than 25 mg/Day on Plasma Potassium ConcentrationCardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolization, arrhythmias, postmenopausal state and as anti-oxidants.Management of Cardio-Renal Syndrome and Diuretic Resistance.
P2860
Q24644755-85A17F74-5E0F-4C78-B80A-C5FB6F5E2344Q26741152-03112808-E2A7-4C65-8C8C-CBB7B7D3EE85Q28066549-56ED2700-B9EC-4F43-A2B9-0311F442343BQ28067064-794BE156-BC8F-4CA5-AB4D-FCEEBCB12440Q34093630-472AE554-5E9C-48FB-A583-37171414B888Q34366011-0C8D88C4-8083-4381-B950-5507FACEB965Q35272248-375242A6-558B-46E8-B0CD-947456740E17Q35580143-57FBEDD4-CD4A-4061-9774-6C750730F070Q35715750-A4809D82-D9F0-4E0C-B194-6F99ECF26F60Q36319066-22FFBCB8-4D63-4C22-B8C1-11B685819835Q36716456-289FBE97-B2A4-469C-812E-8D498260BA0AQ37308522-7E557B50-EE50-4A57-9343-26BD7B750F06Q37401651-D86E600C-9A31-4AE4-BBE4-FBD21E0D7002Q37889518-0FFEC9E0-BF04-4FD2-99E4-B6E7F619CF9EQ38040730-3A964584-E86C-4608-934E-E3AF05F09033Q38307958-27732FA2-E524-40A1-AE3C-DA7BE4A11044Q38374127-A28A787C-8CB4-49F5-A1C5-FF2F99B68706Q38536675-09AF9B77-5777-45D3-87D0-56DCDC390335Q38612606-92EB4AED-F08E-4B90-B7BC-EDAD9D865647Q38927295-DE881EFF-2C46-46E1-A30A-B21048B7397AQ39154039-A01B839D-1734-4A82-8426-A5619A472190Q39203291-0751F5C5-784E-4A94-BCE4-1D658435F5B8Q39448164-56D1F876-5C3B-421B-A502-953116FB7375Q41090275-A749633B-F3B5-4758-B46B-E267158F070DQ41476569-5C921A68-2D65-480F-8BF9-4B90F2E5BA23Q41775279-7D8FE241-0C43-4CAC-94C7-95C85AFA0E39Q43238841-5DDDE772-7081-407E-92B2-AE6E310565EFQ50888057-6C32D0F6-6590-4735-B284-C4C36DF48200
P2860
Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Spironolactone in congestive h ...... n-converting enzyme inhibitor.
@en
Spironolactone in congestive h ...... n-converting enzyme inhibitor.
@nl
type
label
Spironolactone in congestive h ...... n-converting enzyme inhibitor.
@en
Spironolactone in congestive h ...... n-converting enzyme inhibitor.
@nl
prefLabel
Spironolactone in congestive h ...... n-converting enzyme inhibitor.
@en
Spironolactone in congestive h ...... n-converting enzyme inhibitor.
@nl
P2093
P1476
Spironolactone in congestive h ...... n-converting enzyme inhibitor.
@en
P2093
A A van Vliet
A J Donker
F W Verheugt
P304
P356
10.1016/0002-9149(93)90241-4
P407
P577
1993-01-01T00:00:00Z